Over the past quarter of a century, invasive fungal infections have emerged as an important cause of morbidity and mortality in immunocompromised patients. Although several new antifungal drugs have been licensed in recent years, antifungal drug resistance is becoming a major concern during treatment of such patients. The resistance may be intrinsic, acquired or clinical. The understanding of t...